SNS 314 mesylate

Key Product Details

Product Description

SNS 314 mesylate is a potent, ATP-competitive Aurora kinase inhibitor (IC₅₀ values are 3, 9 and 31 nM for Aurora C, A and B, respectively). Exhibits both in vitro and in vivo activity against human cancer cell lines and tumor xenograft models. Displays additive antiproliferative effects in combination with chemotherapeutics such as carboplatin (Cat. No. 2626), gemcitabine (Cat. No. 3259) and 5-fluorouracil (Cat. No. 3257).

Product Specifications for SNS 314 mesylate

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SNS 314 mesylate

The following data is based on the product molecular weight 527.04.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.90 mL	9.49 mL	18.97 mL
5 mM	0.38 mL	1.90 mL	3.79 mL
10 mM	0.19 mL	0.95 mL	1.90 mL
50 mM	0.04 mL	0.19 mL	0.38 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• VanderPorten The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol.Cancer Ther. 2009 PMID: 19372566
• Oslob Discovery of a potent and selective Aurora kinase inhibitor. Bioorg.Med.Chem.Lett. 2008 PMID: 18678489
• Arbitrario SNS-314, a pan-Aurora kinase inhibitor, shows potent and anti-tumor activity and dosing flexibility in vivo. Cancer Chemother. Pharmacol. 2010 PMID: 19649632

Product Documents for SNS 314 mesylate